title: HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.
abstract: Histone deacetylase (HDAC) inhibitors are cancer treatments that inhibit the removal of the epigenetic modification acetyllysine on histones, resulting in altered gene expression. Such changes in expression may influence other histone epigenetic modifications. We describe a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify lysine acetylation and methylation and arginine methylation on histones extracted from cultured cells treated with HDAC inhibitors. The HDAC inhibitors vorinostat, mocetinostat and entinostat induced 400-600% hyperacetylation in HEK 293 and K562 cells. All HDAC inhibitors decreased histone methylarginines in HEK 293 cells but entinostat produced dose dependent reductions in asymmetric dimethylarginine, not observed in K562 cells. Vorinostat produced increases in histone lysine methylation and decreased expression of some lysine demethylases (KDM), measured by quantitative PCR. Entinostat had variable effects on lysine methylation and decreased expression of some KDM while increasing expression of others. Mocetinostat produced dose dependent increases in histone lysine methylation by LC-MS/MS. This was corroborated with a multiplex colorimetric assay showing increases in histone H3 lysine 4, 9, 27, 36 and 79 methylation. Increases in lysine methylation were correlated with dose dependent decreases in the expression of seven KDM. Mocetinostat functions as an HDAC inhibitor and a de facto KDM inhibitor.
authors.affiliation: Faculty of Health Sciences, College of Pharmacy, Pharmaceutical Analysis Laboratory, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Ryan
authors.initials: R
authors.lastname: Lillico
authors.affiliation: Faculty of Health Sciences, College of Pharmacy, Pharmaceutical Analysis Laboratory, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Marina Gomez
authors.initials: MG
authors.lastname: Sobral
authors.affiliation: Faculty of Health Sciences, College of Pharmacy, Pharmaceutical Analysis Laboratory, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Stesco
authors.affiliation: Faculty of Health Sciences, College of Pharmacy, Pharmaceutical Analysis Laboratory, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: ted.lakowski@umanitoba.ca.
authors.forename: Ted M
authors.initials: TM
authors.lastname: Lakowski
mesh_terms: D001120:Arginine / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D057809:HEK293 Cells; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D056466:Histone Demethylases / Q000096:biosynthesis*; D006657:Histones / Q000378:metabolism*; D006801:Humans; D020014:K562 Cells; D008239:Lysine / Q000378:metabolism; D008745:Methylation / Q000187:drug effects; D053719:Tandem Mass Spectrometry
chemical_list: D056572:Histone Deacetylase Inhibitors; D006657:Histones; D001120:Arginine; D056466:Histone Demethylases; D008239:Lysine
keywords: Epigenetics; HDAC inhibitor; Histone acetylation; Histone methylation; LC–MS/MS; Lysine demethylase